C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018 - ResearchAndMarkets.com

DUBLIN--()--The "C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018 provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 20+ products along with 18+ companies involved. Dompe Farmaceutici, BioLineRx, and X4 Pharmaceuticals are among the developers of most promising pipeline products.

Products covered by Phase:

  • Marketed Products
  • Phase III, Phase II and Phase I
  • Pre-clinical and Discovery

Overview of pipeline development activities for C-X-C Chemokine Receptor (CXCR) Inhibitors

Pipeline analysis of 20+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for C-X-C Chemokine Receptor (CXCR) Inhibitors

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

Key Topics Covered:

Executive Summary

Overview

Introduction

Structure of CXC Receptors

Key CXCR Inhibitors as Drug Targets

CXCR4 Inhibitor

Mechanism of Action

CXCR4 in Different Indications

CXCR4 in Rheumatoid Arthritis

CXCR4 and WHIM syndrome

CXCR4 and Metabolic Disorders

Competitive Landscape - Active Products

Active Pipeline Coverage by Indication

Marketed and Pipeline Products

Marketed Products

Mozobil: Sanofi Genzyme

Product Description

Regulatory Milestones

Research and Development

Other Clinical Activities

Product Development Activities

Global Sales of Mozobil

Historical and Forecasted Global Sales (2015-2027)

Mozobil - Analyst Insights

CXCR Inhibitors Class Share Evolution

Pipeline Therapeutics (Active Products)

Pipeline Therapeutics (Inactive Products)

Comparative Analysis

Late Stage Products (Phase III)

Comparative Analysis

Reparixin: Dompe Farmaceutici

Product Description

Research and Development

Product Development Activities

Reparixin Forecasted Sales

Reparixin - Analyst Insights

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I)

Comparative Analysis

Pre-clinical and Discovery Stage Products

Comparative Analysis

Therapeutic Assessment: Active Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Dormant & Discontinued Products

Comparative Analysis

Companies Mentioned

  • AstraZeneca
  • Biokine Therapeutics
  • BioLineRx
  • Bristol-Myers Squibb
  • ChemoCentryx
  • Dompe Farmaceutici
  • Eli Lilly
  • Genentech
  • Genzyme Corporation
  • GlaxoSmithKline
  • Globavir Biosciences
  • GlycoMimetics
  • Harmonic Pharma
  • Pfizer
  • Pharis Bioetec
  • Pierre Fabre
  • Polyphor
  • QUE Oncology
  • Syntrix Biosystems
  • Upsher-Smith Laboratories
  • X4 Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/688qd8/cxc_chemokine?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs